BofA moved to No Rating from Buy on Amicus Therapeutics (FOLD) after the company announced that it has entered into an agreement to be acquired by BioMarin (BMRN). Given the deal announcement, Amicus is no longer trading on its fundamentals, the analyst says.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD: